Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gandotinib |
Synonyms | |
Therapy Description |
Gandotinib (LY2784544) is an ATP-competitive inhibitor of JAK2, including JAK2 V617F, which decreases downstream signaling and may reduce cell proliferation (PMID: 23584399). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gandotinib | LY2784544 | JAK2 Inhibitor - ATP competitive 15 | Gandotinib (LY2784544) is an ATP-competitive inhibitor of JAK2, including JAK2 V617F, which decreases downstream signaling and may reduce cell proliferation (PMID: 23584399). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | myeloproliferative neoplasm | predicted - sensitive | Gandotinib | Phase I | Actionable | In a Phase I trial, treatment with Gandotinib (LY2784544) demonstrated safety in myeloproliferative neoplasm patients harboring JAK2 V617F and resulted in clinical improvement as best response in 29% (9/31) patients with myelofibrosis (PMID: 28934680). | 28934680 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|